Borderline Lepromatous Leprosy with Severe Erythema Nodosum Leprosum: A Case Report
Downloads
Background: Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae (M. leprae) that primarily infects Schwann cells in the peripheral nerves, leading to nerve damage and the development of disabilities. In 2018, Indonesia was the third country with the most leprosy cases in the world. Erythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy. Purpose: To report a case of borderline lepromatous leprosy with severe ENL. Case: A 49-year-old Balinese man presented with multiple tender erythematous skin nodules all over his body, fever, arthralgia, bilateral cervical lymphadenopathy, and sensory loss for the past week. The acid-fast bacilli bacteriological examination showed a positive result. The patient was diagnosed with borderline lepromatous (BL) leprosy with severe ENL and was treated with multibacillary multidrug therapy (MB MDT), methylprednisolone, and other symptomatic medications. After 1 month of treatment, there was an improvement in skin lesions. The MB-MDT treatment was continued and methylprednisolone was planned to be tapered down gradually. Discussion: Approximately 20-50% of all leprosy patients show leprosy reactions in the course of the disease. The goals of treatment for severe ENL are to control inflammation, reduce pain, treat neuritis to prevent nerve dysfunction and contractures, and prevent recurring ENL. The prognosis of leprosy with ENL reactions depends on the severity of the occurring leprosy reaction; early diagnosis and prompt treatment; and patient compliance with treatment. Conclusion: Early diagnosis and treatment are essential to avoid deformities in leprosy patients.
Zhu J, Yang D, Shi C, Jing Z. Therapeutic dilemma of refractory erythema nodosum leprosum. Am J Trop Med Hyg 2017; 96(6): 1362-4.
Silva MR, Castro MC. Mycobacterial Infections. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology 4th ed. New York: Elsevier; 2018. p. 1296-303.
Arlong J, Govindharaj P, Darlong F, Mahato N. A study of untreated leprosy-affected children reporting grade 2 disability at a referral center in West Bengal, India. Lepr Rev 2017; 88: 298-305.
Williams A, Thomas EA, Bhatia A, Samuel CJ. Study of Clinical Spectrum and Factors Associated with Disabilities in Leprosy: a Ten Year Retrospective Analysis. Indian J Lepr. 2019; 91: 37-45.
World Health Organization. Global Leprosy Update 2018: Moving Towards A Leprosy-Free World. WHO Weekly Epidemiological Record. 2019; 35: 389-412.
Sub Divisi Morbus Hansen Poliklinik Kulit dan Kelamin. Register Kunjungan Sub Divisi Morbus Hansen Poliklinik Kulit dan Kelamin Rumah Sakit Umum Pusat Sanglah Tahun 2018-2019. Denpasar; 2019.
Kumar B, Dogra S. Case Definition and Clinical Types of Leprosy. In: Kumar B, Kar HK, editors. IAL Textbook of Leprosy 2nd ed. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2017.p. 236-53.
Maymone MBC, Laughter M, Venkatesh S, Dacso MM, Rao PN, et al. Leprosy: Clinical Aspects and Diagnostic Techniques. J Am Acad Dermatol. 2020; 83: 1-14.
Scollard DM, Martelli CM, Stefani MM, Maroja Mde F, Villahermosa L, et al. Risk Factors for Leprosy Reactions in Three Endemic Countries. The American Journal of Tropical Medicine and Hygiene. 2015; 92: 108-14.
Nery JA, Bernardes FF, Quintanilha J, Machado AM, Oliveira S, Sales AM. Understanding The Type 1 Reactional State for Early Diagnosis and Treatment: A Way to Avoid Disability in Leprosy. An Bras Dermatol. 2013; 88(5): 787-92.
Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Leprosy Reaction in Thai Population: A 20-year Retrospective Study. Dermatol Res Pract. 2015: 1-5.
Salgado CG, Brito AC, Salgado UI, Spencer JS. Leprosy. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick's Dermatology. 9th ed. New York: McGraw-Hill; 2019. p. 2892-924.
Lockwood DNJ. Chronic Aspects of Leprosy-Neglected but Important. Trans R Soc Trop Med Hyg. 2019; 113(12): 813-7.
Habibie DP, Listiawan MY. Penggunaan Thalidomide pada Pasien Lepra dengan Erythema Nodosum Leprosum yang Ketergantungan Steroid: Sebuah Laporan Kasus. 2016; 28(2): 90-6.
Lastoria JC, Abreu MA. Leprosy: Review Of The Epidemiological, Clinical, and Etiopathogenic Aspects-Part 1. An Bras Dermatol. 2014; 89(2): 205-18.
Bhat RM, Prakash C. Leprosy: An Overview of Pathophysiology. Interdiscip Perspect Infect Dis. 2012; 7(2): 1-6.
Roberta OP, Jorgenilce de SS, Elizabeth PS. Mycobacterium Leprae-Host Cell Interactions and Genetic Determinants in Leprosy: An Overview. Future Microbiol. 2011; 6(2): 217-30.
Richardus JH, Oskam L. Protecting People Against Leprosy: Chemoprophylaxis and immunoprophylaxis. Clinics in Dermatology. 2015; 33(2): 19-25.
World Health Organization. Guidelines for the diagnosis, treatment, and prevention of leprosy. New Delhi: World Health Organization, Regional Office for South East Asia; 2017.
Wardana M, Swastika M, Rusyati LM. Subclinical Leprosy Detection in Contact Person of Multibacillary Leprosy Patients. Indonesia Journal of Biomedical Science. 2016; 10(2): 10-4.
Podder I, Saha A, Bandyopadhyay D. Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at The End of 6 Months: A Prospective Observational Study from Eastern India. Indian J Dermatol. 2018; 63(1): 47–52
Darmawan H, Rusmawardiana. Sumber dan Cara Penularan Mycobacterium leprae. Tarumanegara Medical Journal. 2020; 2(2): 390-401.
Costa PDSS, Fraga LR, Kowalski TW, Daxbacher ELR, Schuler-Faccini L, Vianna FSL. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. Acta Trop. 2018; 183: 134-41.
Geani S, Rahmadewi R, Astindari A, Prakoeswa CRS, Sawitri S, Ervianti E, et al. Profile of Disability in Leprosy Patients: A Retrospective Study. BIKKK. 2022; 34(2): 109-13.
Fransisca C, Zulkarnain I, Ervianti E, Damayanti D, Sari M, Budiono B, et al. A Retrospective Study: Epidemiology, Onset, and Duration of Erythema Nodosum Leprosum in Surabaya, Indonesia. BIKKK. 2021; 33(1): 8-12.
Copyright (c) 2022 Berkala Ilmu Kesehatan Kulit dan Kelamin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
